A Single-arm Phase II Study of Alemtuzumab in Combination With High-dose Methylprednisolone in CLL Patients With p53 Deletion

NCT00292760 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukaemia

Interventions

DRUG: Alemtuzumab
DRUG: Methyprednisolone

Sponsor

Royal Marsden NHS Foundation Trust